Gene therapy safety check: 400 cancer patients monitored for years

NCT ID NCT06885424

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for delayed side effects and see how long any benefits last. The goal is to better understand the safety and durability of this gene therapy approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal carcinoma colorectal neoplasm head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma kidney cancer malignant pancreatic neoplasm mesothelioma neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma pancreatic neoplasm renal cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Banner Health

    Gilbert, Arizona, 85234, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NYU Langone Medical Center

    New York, New York, 10016, United States